Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study

Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study

Abstract Introduction Faricimab is a bispecific antibody that enables greater disease control and extended durability compared with vascular endothelial growth factor (VEGF) inhibition alone in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This study aimed to...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Lupidi, Cristiana Iaculli, Luisa Marco, Settimio Rossi, Emilia Sicari, Giulia Villa, Vittorio Pirani
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Ophthalmology and Therapy
Subjects:
Vascular endothelial growth factor A
Faricimab
Neovascular age-related macular degeneration
Diabetic macular edema
Retrospective studies
Italy
Online Access:https://doi.org/10.1007/s40123-025-01204-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40123-025-01204-0

Similar Items